BRPI0414551A8 - Formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo - Google Patents

Formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo

Info

Publication number
BRPI0414551A8
BRPI0414551A8 BRPI0414551A BRPI0414551A BRPI0414551A8 BR PI0414551 A8 BRPI0414551 A8 BR PI0414551A8 BR PI0414551 A BRPI0414551 A BR PI0414551A BR PI0414551 A BRPI0414551 A BR PI0414551A BR PI0414551 A8 BRPI0414551 A8 BR PI0414551A8
Authority
BR
Brazil
Prior art keywords
active agent
pharmaceutical formulation
inhibiting
delaying
crystallization
Prior art date
Application number
BRPI0414551A
Other languages
English (en)
Inventor
Norberto R Carrara Dario
Grenier Arnaud
Besse Celine
Original Assignee
Antares Pharma Ipl Ag
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Pharma Ipl Ag, Ferring Bv filed Critical Antares Pharma Ipl Ag
Publication of BRPI0414551A publication Critical patent/BRPI0414551A/pt
Publication of BRPI0414551A8 publication Critical patent/BRPI0414551A8/pt
Publication of BRPI0414551B1 publication Critical patent/BRPI0414551B1/pt
Publication of BRPI0414551B8 publication Critical patent/BRPI0414551B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAÇÃO FARMACÊUTICA TRANSDÉRMICA OU TRANSMUCOSA E MÉTODO DE PROTELAÇÃO OU INIBIÇÃO DA CRISTALIZAÇÃO DE UM AGENTE ATIVO. Esta invenção relaciona-se com nova formulação farmacêutica transdérmica ou transmucosa, que reduz as ocorrências de comtaminação de outros indivíduos e a transferência para a roupa do usuário. A formulação nova inclui pelo menos um ingrediente farmacológicamente ativo e um sistema de solvente tendo um éter monoalquil de dietilenoglicol e um glicol, presentes em proporções especificadas e uma mistura de água e álcool. A invenção também se relaciona com um método de inibição ou protelação de cristalização de um agente ativo numa formulação farmacêutica.
BRPI0414551A 2003-10-10 2004-10-06 formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo BRPI0414551B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51061303P 2003-10-10 2003-10-10
US60/510,613 2003-10-10
PCT/EP2004/011175 WO2005039531A1 (en) 2003-10-10 2004-10-06 Transdermal pharmaceutical formulation for minimizing skin residues

Publications (4)

Publication Number Publication Date
BRPI0414551A BRPI0414551A (pt) 2006-10-31
BRPI0414551A8 true BRPI0414551A8 (pt) 2017-04-11
BRPI0414551B1 BRPI0414551B1 (pt) 2020-08-18
BRPI0414551B8 BRPI0414551B8 (pt) 2021-05-25

Family

ID=34520020

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414551A BRPI0414551B8 (pt) 2003-10-10 2004-10-06 formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo

Country Status (15)

Country Link
US (3) US7335379B2 (pt)
EP (1) EP1670433B1 (pt)
JP (1) JP5619337B2 (pt)
AT (1) ATE534373T1 (pt)
AU (1) AU2004283431B2 (pt)
BR (1) BRPI0414551B8 (pt)
CA (1) CA2538856C (pt)
DK (1) DK1670433T3 (pt)
ES (1) ES2377932T3 (pt)
MX (2) MXPA06003316A (pt)
NZ (1) NZ546106A (pt)
PL (1) PL1670433T3 (pt)
PT (1) PT1670433E (pt)
WO (1) WO2005039531A1 (pt)
ZA (1) ZA200602046B (pt)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
ES2265239B1 (es) * 2004-09-23 2008-02-01 Laboratorio Reig Jofre, S.A. Composicion farmaceutica para administracion transdermica.
EP1858495A2 (en) * 2005-02-14 2007-11-28 Neurogesx, Inc. Device for delivery of trpv1 agonists
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
ZA200711040B (en) 2005-06-03 2009-04-29 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
US20070004693A1 (en) * 2005-06-16 2007-01-04 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
CA2612380C (en) 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
GB0517840D0 (en) * 2005-09-02 2005-10-12 Henderson Morley Plc Topical anti viral formulations
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
FR2900575B1 (fr) * 2006-05-05 2008-10-17 Anteis Sa Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
RU2009117468A (ru) * 2006-10-12 2010-11-20 Рото Фармасьютикал Ко., Лтд. (Jp) Наружный препарат для кожи
US20100048628A1 (en) * 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
NZ578883A (en) 2007-01-11 2012-05-25 Acrux Dds Pty Ltd Open top applicator for spreading liquid on skin
WO2008089242A1 (en) * 2007-01-16 2008-07-24 Dermworx, Incorporated Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
US9283177B2 (en) * 2007-01-16 2016-03-15 Juventio, Llc Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
WO2008128280A1 (en) * 2007-04-20 2008-10-30 Acrux Dds Pty Ltd Method and system for transdermal administration of volatile active
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
RU2499583C2 (ru) * 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US8927537B2 (en) * 2007-12-21 2015-01-06 Nuvo Research Inc. Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
KR20110020788A (ko) * 2008-05-30 2011-03-03 에자이 알앤드디 매니지먼트 가부시키가이샤 경피 흡수 제제
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
BRPI0913809B1 (pt) * 2008-10-02 2019-02-05 Mylan Inc método para produzir continuamente um laminado adesivo sensível á pressão multicamada
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
HUP0900073A2 (en) * 2009-02-06 2010-11-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process and equipment for inquiry medical product on dermal surface
WO2011000210A1 (zh) * 2009-07-01 2011-01-06 润和生物医药科技(汕头)有限公司 促渗剂组合物及其透皮给药系统中的应用
JP5675225B2 (ja) * 2009-09-01 2015-02-25 久光製薬株式会社 貼付製剤
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
MX2012012069A (es) 2010-04-30 2012-11-22 Teikoku Pharma Usa Inc Composiciones transdermicas de propinilaminoindan.
GB2482868A (en) * 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
EP2646015B1 (en) * 2010-12-02 2020-04-22 Ferring International Center S.A. Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2672847B1 (de) 2011-02-11 2015-04-22 Batmark Limited Inhalatorkomponente
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
KR102568894B1 (ko) * 2011-05-15 2023-08-21 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
RU2634638C2 (ru) * 2011-06-27 2017-11-02 Ферринг Б.В. Аппликаторная система для нанесения вязкой жидкости на кожу человека
JP5820207B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820206B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP2013060393A (ja) * 2011-09-13 2013-04-04 Nitto Denko Corp 経皮吸収促進用組成物および貼付製剤
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
CN103181894B (zh) * 2011-12-30 2015-07-15 北大方正集团有限公司 萘丁美酮喷雾剂及其制备方法
KR101976137B1 (ko) 2012-01-25 2019-05-09 한미약품 주식회사 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
CN104428003B (zh) 2012-07-12 2020-03-10 辉凌公司 双氯芬酸制剂
JP6226278B2 (ja) * 2012-08-03 2017-11-08 国立大学法人愛媛大学 免疫細胞の活性化抑制剤およびその用途
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
JP6629286B2 (ja) 2014-03-18 2020-01-15 アンスティテュ・ドゥ・ルシェルシュ・アン・セミオシミー・エ・エソロジー・アプリケＩｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｈｅｒｃｈｅ Ｅｎ Ｓｅｍｉｏｃｈｉｍｉｅ Ｅｔ Ｅｔｈｏｌｏｇｉｅ Ａｐｐｌｉｑｕｅｅ ネコ鎮静フェロモン
CN106413695B (zh) 2014-04-08 2019-12-10 帝国制药美国公司 利伐斯的明透皮组合物及其使用方法
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
MX2017008423A (es) 2014-12-23 2017-10-26 Hoffman Steven Formulaciones transdérmicas.
EP4122460A1 (en) 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US20180133239A1 (en) * 2015-06-08 2018-05-17 Dermarc LLC Therapeutic composition
BR112017026294A2 (pt) * 2015-06-08 2018-09-18 Dermarc LLC formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017057743A1 (ja) * 2015-09-30 2017-04-06 富士フイルム株式会社 経皮吸収用組成物
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
WO2017085687A1 (en) 2015-11-20 2017-05-26 West-Ward Pharmaceuticals International Limited Stable formulation of phenobarbital sodium injection
WO2017117554A1 (en) 2015-12-30 2017-07-06 Corium International, Inc. Systems and methods for long term transdermal administration
WO2017214201A1 (en) * 2016-06-06 2017-12-14 Thesan Pharmaceuticals, Inc. Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same
WO2017218783A1 (en) * 2016-06-17 2017-12-21 Benchmark Cosmetic Laboratories, Inc. Sphere forming compositions
AU2017281789B2 (en) 2016-06-23 2023-04-13 Corium, LLC. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
WO2018022818A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Memantine transdermal delivery systems
EP3490559A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
US10300025B2 (en) 2016-07-27 2019-05-28 Corium, Inc. Donepezil transdermal delivery system
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
EP4729123A2 (en) 2017-04-24 2026-04-22 Alto Neuroscience, Inc. Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
GB2562270B (en) 2017-05-10 2020-07-01 Hyphens Pharma Pte Ltd Skin barrier composition
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2019012353A1 (en) 2017-07-11 2019-01-17 Shilpa Medicare Limited TOPICAL COMPOSITIONS OF DUTASTERIDE
JP7269918B2 (ja) 2017-09-01 2023-05-09 ジェイダブリュ ファーマセウティカル コーポレーション デュタステリドを含む固形製剤およびその製造方法
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
AU2019299538B2 (en) 2018-07-05 2025-05-08 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020097284A1 (en) * 2018-11-08 2020-05-14 Jindal Vinay K TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
JP6908800B1 (ja) * 2019-09-18 2021-07-28 久光製薬株式会社 ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法
RU2736081C1 (ru) * 2019-12-02 2020-11-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Пластырь трансдермальный с гликлазидом
WO2021113411A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
EP4090333A1 (en) * 2020-01-13 2022-11-23 Starton Therapeutics, Inc. Treatment of vomiting and nausea with minimum dose of olanzapine
KR102352888B1 (ko) 2020-01-15 2022-01-18 한국프라임제약주식회사 두타스테리드를 포함하는 경구용 약제학적 조성물
MX2022010593A (es) 2020-02-27 2022-12-13 Ferring Bv Composiciones tópicas de diclofenaco y métodos.
WO2021189077A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
US12508221B2 (en) * 2020-09-11 2025-12-30 PS Therapy Ltd Topical compositions and methods of use
US20220133658A1 (en) * 2020-09-11 2022-05-05 Ps Therapy, Inc. Topical analgesic compositions and methods of use
JP2023550085A (ja) * 2020-11-23 2023-11-30 ダーマバント、サイエンシーズ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング タピナロフのゲル、軟膏、およびフォーム製剤ならびに使用方法
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN115414320A (zh) * 2022-09-14 2022-12-02 四川农业大学 一种具有抗真菌作用的1,8-桉叶油素纳米乳凝胶剂
EP4586999A1 (en) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
EP4611735A2 (en) * 2022-11-04 2025-09-10 Celista Pharmaceuticals Llc Topical oxybutynin for hot flashes
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1979385A (en) * 1931-11-10 1934-11-06 Carbide & Carbon Chem Corp Cosmetic preparation
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3143465A (en) * 1961-06-19 1964-08-04 Wallace & Tiernan Inc Pharmaceutical preparations comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon; and treatment therewith
US3650280A (en) * 1969-12-03 1972-03-21 David Roberts Cosmetic treatment of hair with thiourea or urea and glyoxal
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
FR2518879A1 (fr) 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5783207A (en) 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
DE3522550A1 (de) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US5731303A (en) * 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
CA1272922A (en) 1986-06-03 1990-08-21 Peter William Berry Drug delivery device, its preparation and use
EP0249397B1 (en) 1986-06-13 1992-08-12 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4908389A (en) 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
MY102980A (en) 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5925372A (en) * 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5225189A (en) * 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US4942158A (en) 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
KR930001804B1 (ko) 1989-02-28 1993-03-13 데이진 가부시끼가이샤 첩부제 및 그의 제조방법
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
DE69007886T2 (de) 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US4956171A (en) 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5230896A (en) 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JP3273430B2 (ja) 1989-12-28 2002-04-08 日東電工株式会社 エストロゲン含有ゲル製剤
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5371005A (en) 1990-04-10 1994-12-06 Kyowa Hakko Kogyo Co., Ltd. Cholesterol oxidase
US5602017A (en) * 1990-04-10 1997-02-11 Kyowa Hakko Kogyo Co., Ltd. Cholesterol oxidase
US5149719A (en) 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK0540613T3 (da) 1990-07-20 1996-04-01 Tillotts Pharma Ag Produkter og fremgangsmåder til behandling af fordøjelseskanalen
JP2883700B2 (ja) 1990-08-24 1999-04-19 花王株式会社 毛髪化粧料
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
FR2668945B1 (fr) 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5175190A (en) 1991-02-15 1992-12-29 The University Of British Columbia Medium chain fatty acids of C8-10 for the treatment of skin lesions
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US5178879A (en) * 1992-04-17 1993-01-12 Michael Adekunle Capsaicin gel
US5453279A (en) 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5278176A (en) 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5458884A (en) 1992-09-10 1995-10-17 Britton; Peter Bioerodible device for administering active ingredients
FR2695826B1 (fr) 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
JP2937667B2 (ja) * 1992-11-19 1999-08-23 高砂香料工業株式会社 尋常性ざ瘡用皮膚外用剤
WO1994012146A1 (en) 1992-11-23 1994-06-09 Estee Lauder, Inc. Self-tanning cosmetic compositions and methods of using the same
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311252A1 (de) * 1993-04-06 1994-10-13 Boehringer Mannheim Gmbh Bestimmung eines Analyten in einer Probeflüssigkeit
US5576279A (en) 1993-05-17 1996-11-19 Helene Curtis, Inc. Stable conditioning shampoo containing an anionic surfactant a fatty alcohol, and polyethyleneimine
US5503844A (en) 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE69422925T2 (de) 1993-07-09 2000-08-17 Cygnus, Inc. Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten
JP3223404B2 (ja) 1993-10-30 2001-10-29 日本ソシア株式会社 育毛・養毛剤
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
WO1995029678A1 (en) * 1994-04-28 1995-11-09 F.Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
US5552153A (en) 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
FR2722102B1 (fr) * 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US6309843B1 (en) 1994-10-25 2001-10-30 The Curators Of The University Of Missouri Glycoprotein for use in determining endometrial receptivity
US5831035A (en) 1994-10-25 1998-11-03 Curators Of The University Of Missouri Antibody against human endometrial stromal cell glycoprotein
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US6124355A (en) 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
ES2098193B1 (es) 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
JP4036496B2 (ja) 1995-10-24 2008-01-23 リンテック株式会社 ゲル製剤の製造方法
US5817527A (en) 1995-11-06 1998-10-06 Chiron Diagnostics Corporation Conjugation of ligand to immobilized protein in organic solvent
DE19548332A1 (de) 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
EP0785211A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
EP0785212A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
AU2036297A (en) 1996-03-20 1997-10-10 Glaxo Group Limited Topical formulations of aciclovir
GB9607955D0 (en) 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
US5814659A (en) 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
GB9610862D0 (en) * 1996-05-23 1996-07-31 Evans Brian K Pharmaceutical products
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US20010023261A1 (en) 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
WO1998040094A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
IT1289973B1 (it) 1997-02-25 1998-10-19 Helsinn Healthcare Sa Sistemi gelificati di nimesulide per uso topico
US6093722A (en) * 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
US6426078B1 (en) 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
WO1998056422A1 (en) 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6034079A (en) 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
GB9720470D0 (en) 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6319913B1 (en) 1997-11-10 2001-11-20 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US20010038855A1 (en) 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
ATE399565T1 (de) 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913732A1 (de) 1999-03-26 2000-09-28 Lohmann Therapie Syst Lts Nikotin-TTS mit einem Zusatz von Monoterpenketonen
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6451300B1 (en) 1999-05-03 2002-09-17 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
FR2798065B1 (fr) 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6432446B2 (en) * 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20070225379A1 (en) 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6545046B2 (en) * 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
EP1322336B1 (en) 2000-08-30 2013-07-03 Unimed Pharmaceuticals, LLC Method of increasing testosterone and related steroid concentrations in women
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
CA2359813C (en) 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
US6479076B2 (en) 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
AU2002243643A1 (en) 2001-01-25 2002-08-06 Yale University Estradiol-16alpha-carboxylic acid esters as locally active estrogens
EP1231158A1 (de) * 2001-02-12 2002-08-14 Hellermann Tyton GmbH Magazinstreifen von Bandschlössern und Werkzeug für dessen Verarbeitung
WO2003028667A2 (en) 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
US6951846B2 (en) 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
US6586449B1 (en) 2002-05-28 2003-07-01 Cambrex Charles City, Inc. Nicotine-containing, controlled release composition and method
US6889875B2 (en) 2002-06-04 2005-05-10 Cellegy Pharmaceuticals, Inc. Taper well meter dose pump
DE10253216A1 (de) * 2002-11-15 2004-05-27 Cognis Deutschland Gmbh & Co. Kg Verwendung von niedermolekularen Proteinhydrolysaten in Wasch- und Reinigungsmitteln
US6995265B2 (en) 2003-08-26 2006-02-07 North Carolina State University Synthesis of nicotine derivatives from nicotine
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
FR2877143A1 (fr) * 2004-10-25 2006-04-28 St Microelectronics Sa Cellule de memoire volatile preenregistree
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070048360A1 (en) * 2005-08-23 2007-03-01 R Carrara Dario N Pharmaceutical compositions with melting point depressant agents and method of making same

Also Published As

Publication number Publication date
BRPI0414551B8 (pt) 2021-05-25
MX343811B (es) 2016-11-24
BRPI0414551B1 (pt) 2020-08-18
WO2005039531A1 (en) 2005-05-06
EP1670433B1 (en) 2011-11-23
ES2377932T3 (es) 2012-04-03
US8980309B2 (en) 2015-03-17
JP2007508261A (ja) 2007-04-05
DK1670433T3 (da) 2012-03-12
ATE534373T1 (de) 2011-12-15
CA2538856A1 (en) 2005-05-06
CA2538856C (en) 2010-06-29
BRPI0414551A (pt) 2006-10-31
US20060153905A1 (en) 2006-07-13
ZA200602046B (en) 2007-06-27
MXPA06003316A (es) 2006-06-08
AU2004283431B2 (en) 2009-09-10
PT1670433E (pt) 2012-02-08
US7335379B2 (en) 2008-02-26
US20090069364A1 (en) 2009-03-12
NZ546106A (en) 2008-10-31
PL1670433T3 (pl) 2013-03-29
EP1670433A1 (en) 2006-06-21
US20110257141A1 (en) 2011-10-20
AU2004283431A1 (en) 2005-05-06
JP5619337B2 (ja) 2014-11-05

Similar Documents

Publication Publication Date Title
BRPI0414551A8 (pt) Formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
SE0100901D0 (sv) New composition
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
MXPA05002814A (es) Formulacion para agentes lipofilicos.
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
ATE429920T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von hypogonadismus
TR200101412T2 (tr) Yeni bileşikler.
DK1459065T3 (da) Fremgangsmåde til målingen af styrken af glatirameracetat
MY142044A (en) Endoparasiticidal compositions for topical application
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
DK1680097T3 (da) Præparater til topisk påföring og fremgangsmåder til afgivelse af et aktivt middel til et substrat
MXPA02009275A (es) Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
NO20060631L (no) Fast dispersjon av takrolimus
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
DK1056454T3 (da) Anvendelse af makrolidforbindelser til behandling af glaukom
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DE60017361D1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
BRPI0513051A (pt) combinação de inibidores de transcriptase reversa e de protease anti-hiv
MA50116B2 (fr) Agent d'absorption transdermique comprenant du donépézil pour le traitement de la démence
EA200702636A1 (ru) Способ и неокклюзивная композиция для трансдермальной доставки лекарственного средства
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 9/06, 47/10

Ipc: A61K 9/06 (2011.01), A61K 47/10 (2011.01), A61P 5/

Free format text: PARA: INT. CL. A61K 9/06, 47/10; A61P 5/24

Ipc: A61K 9/06 (2011.01), A61K 47/10 (2011.01), A61P 5/

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: ANTARES PHARMA IPL AG (CH)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 860160070387 DE 30/03/2016, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO DE CESSAO, CONFORME ART. 18 DO DEC. 13.609/43.

B25A Requested transfer of rights approved

Owner name: FERRING B.V (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2691 DE 02-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.